Eurocor - Life Sciences Technologies Interventional Cardiology Devices Endovascular Therapies

Dediacted to Your heart.
Life Sciences Technology.
Coronary stent technologies and special cardiovascular and endovascluar devices made in Europe for the world.

Eurocor’s partner Micell reported data for MiStentTM DES

Date: 2011/05/27

Bengaluru, India | Bonn, Germany, May 27th, 2011 - Eurocor GmbH is pleased to announce that their partner Micell Technologies presented positive preclinical data at the EuroPCR conference in Paris, France on May 18, 2011 in a presentation titled: "MiStent DES: A Novel Third Generation DES with a Fully-absorbable Coating and Enhanced Drug Delivery Capabilities."
The MiStent Drug-Eluting Coronary Stent System ("MiStent DES") is an ultra-thin, advanced alloy drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation.

In a porcine coronary model, data show continuous and controlled release of Sirolimus, with the MiStent DES coating being eliminated from the stent within 45 to 60 days and fully absorbed in the tissue by 90 days following implant. Preclinical studies additionally demonstrated a positive indication of safety with lower inflammation observed from the MiStent DES compared to the bare metal Abbott MULTI-LINK Vision™ Coronary Stent at 30 and 90 days in the challenging overlapping stents implant configuration.
Sreerangan Kurup, Managing Director of Eurocor GmbH: “Our collaboration with Micell Technologies is bringing together the expertise of both companies to produce a fundamentally different DES. This important and encouraging data underscores the potential overall safety profile and efficacy of MiStent DES.”
 
Clinical trials of the MiStent DES include DESSOLVE I, a study of 30 patients with documented stable or unstable angina pectoris or ischemia, which completed enrollment earlier this year. The primary endpoint is in-stent late lumen loss, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 mm to 3.5 mm and amenable to treatment with a maximum 23 mm long stent. DESSOLVE II is an ongoing multi-center study of approximately 270 patients with documented stable or unstable angina pectoris or ischemia. The primary endpoint is superiority of MiStent DES in minimizing in-stent late lumen loss at nine months, compared to Medtronic's Endeavor® Sprint DES, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 mm to 3.5 mm and amenable to treatment with a maximum 30 mm long stent.
 
In 2009, Maxcor Lifescience, Inc., a subsidiary of Opto Circuits (India) Ltd. entered into a strategic cooperation agreement with Micell Technologies for developing and commercializing leading edge Rapamycin (Sirolimus) – coronary based drug-eluting stents (DES) and drug-eluting balloons (DEB).


Eurocor’s partner Micell Technologies reported preclinical data for MiStentTM Drug-Eluting Coronary Stent at EuroPCR